EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 112.7

Change

-1.08 (-0.95)%

Market Cap

USD 0.70B

Volume

1.26K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.22 (+0.43%)

USD 450.46B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.07 (+0.44%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.10 (+0.38%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.11 (+0.40%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.21 (+0.86%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

-1.10 (-0.71%)

USD 126.93B
8R80:XETRA Amundi Index Solutions - Amund..

+1.14 (+0.83%)

USD 104.09B
JARI:XETRA Amundi Index Solutions - Amund..

+0.21 (+0.47%)

USD 101.29B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.24 (+0.48%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+4.85 (+0.98%)

USD 80.38B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.74% 69% C- 68% D+
Dividend Return 0.25% 26% F 18% F
Total Return 6.99% 70% C- 68% D+
Trailing 12 Months  
Capital Gain 4.49% 37% F 43% F
Dividend Return 0.48% 28% F 11% F
Total Return 4.97% 38% F 42% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.21% 62% D 60% D-
Dividend Return 7.12% 65% D 61% D-
Total Return N/A 56% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 8.42% 67% D+ 74% C
Risk Adjusted Return 84.58% 95% A 94% A
Market Capitalization 0.70B 73% C 65% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike